Trial · NCT04925193

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

NCT04925193, Phase 2, Active not recruiting, University of Colorado, Denver; results first posted 2026-03-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma. Trials, record NCT04925193. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04925193

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
NCT number: NCT04925193
Status: Active not recruiting
Phases: Phase 2
Enrollment: 18 participants, actual
Lead sponsor: University of Colorado, Denver
Conditions: Multiple Myeloma in Relapse
Interventions: Selinexor, Pomalidomide, Daratumumab, Carfilzomib, Dexamethasone
First posted: 2021-06-14
Last updated: 2026-10-02
Results first posted: 2026-03-06

Source ClinicalTrials.gov

Registered outcomes7

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Response Rate	Overall response rate was assessed from C1D1 through 30 days post last dose (approximately 10 months).	To evaluate the overall response rate achieved with physician's choice selinexor-based combination therapy as measured by International Myeloma Working Group criteria (based on Kumar et al 2016).
Secondary	MRD Negative Response Rate	2 years following End of Treatment or date of progression (whichever comes first), assessed up to 2 years	To evaluate the minimal residual disease negative response rate achieved with physician's choice selinexor-based combination therapy assessed via NGS or multiparametric flow cytometry with sensitivity of 10-5.
Secondary	Progression Free Survival	From End of Treatment visit +2 years, or date of progression (whichever comes first), assessed up to 2 years	To evaluate the duration of progression free survival achieved with physician's choice selinexor-based combination therapy
Secondary	Overall Survival	From study start date to study end date or death (whichever comes first), assessed up to 2 years	To evaluate the overall survival achieved with physician's choice selinexor-based combination therapy after 2 years off of study treatment.
Secondary	Duration of Response	End of Treatment +2 years, or date of progression (whichever comes first), assessed up to 2 years	To evaluate the duration of response achieved with physician's choice selinexor-based combination therapy
Secondary	Time to Next Treatment	End of Treatment +2 years, or date of progression (whichever comes first), assessed up to 2 years	To evaluate the time to next treatment achieved with physician's choice selinexor-based combination therapy
Secondary	Safety and Tolerability of Selinexor in Combination With Partner Backbone Agents	From first dose of study drug through 30 days after last dose of protocol required therapies	Occurrence, nature, and severity of adverse events

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Response Rate	End of Therapy, on average 10 months		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	MRD Negative Response Rate	2 years following End of Treatment or date of progression (whichever comes first), assessed up to 2 years	The study sample size was powered to analyze the total group of patients enrolled. It was not powered to analyze each treatment regimen individually.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Progression Free Survival	End of Treatment +2 years, or date of progression (whichever comes first), assessed up to 2 years	The study sample size was powered to analyze the total group of patients enrolled. It was not powered to analyze each treatment regimen individually. This analysis was preplanned in the study protocol. Analysis of the secondary endpoint of progression free survival will be performed on the Intent-to-treat (ITT) population, which will include all subjects who have been enrolled for the study.	Months	MEDIAN
SECONDARY	Overall Survival	EOT + 2 years, or date of progression (whichever comes first)
SECONDARY	Duration of Response	End of Treatment +2 years, or date of progression (whichever comes first), assessed up to 2 years	The study sample size was powered to analyze the total group of patients enrolled. It was not powered to analyze each treatment regimen individually. This analysis was preplanned in the study protocol. Analysis of the secondary endpoint of duration of response will be performed on the Intent-to-treat (ITT) population, which will include all subjects who have been enrolled for the study.	Months	MEDIAN
SECONDARY	Time to Next Treatment	End of Treatment +2 years, or date of progression (whichever comes first), assessed up to 2 years	The study sample size was powered to analyze the total group of patients enrolled. It was not powered to analyze each treatment regimen individually.	Months	MEDIAN

Source ClinicalTrials.gov

Results by group15

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Overall Response Rate	Arm 1	3		Participants
Overall Response Rate	Arm 2	4		Participants
Overall Response Rate	Arm 3	5		Participants
MRD Negative Response Rate	Group 1	0		Participants
MRD Negative Response Rate	Group 2	0		Participants
MRD Negative Response Rate	Group 3	2		Participants
Progression Free Survival	Arm 1	7.6	95% Confidence Interval 2.8 to 12.4	Months
Progression Free Survival	Arm 2	12.7	95% Confidence Interval 4.5 to 20.9	Months
Progression Free Survival	Arm 3	17.2	95% Confidence Interval 3.2 to 31.2	Months
Duration of Response	Group 1	3.08	95% Confidence Interval 0.7 to 6.7	Months

1 to 10 of 15Source ClinicalTrials.gov

See all 15 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Arm 1	3
Overall Study	STARTED	Arm 2	6
Overall Study	STARTED	Arm 3	9
Overall Study	COMPLETED	Arm 1	3
Overall Study	COMPLETED	Arm 2	6
Overall Study	COMPLETED	Arm 3	9
Overall Study	NOT COMPLETED	Arm 1	0
Overall Study	NOT COMPLETED	Arm 2	0
Overall Study	NOT COMPLETED	Arm 3	0

Source ClinicalTrials.gov

Adverse events543

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	General Disorders and Administration Site Conditions	General disorders	Arm 1	0	3	0
other	General Disorders and Administration Site Conditions	General disorders	Arm 2	1	6	1
other	General Disorders and Administration Site Conditions	General disorders	Arm 3	0	9	0
other	General Disorders and Administration Site Conditions	General disorders	Arm 1	0	3	0
other	General Disorders and Administration Site Conditions	General disorders	Arm 2	0	6	0
other	General Disorders and Administration Site Conditions	General disorders	Arm 3	1	9	1
other	General Disorders and Administration Site Conditions	General disorders	Arm 1	0	3	0
other	General Disorders and Administration Site Conditions	General disorders	Arm 2	0	6	0
other	General Disorders and Administration Site Conditions	General disorders	Arm 3	1	9	1
other	Infections and Infestations	Infections and infestations	Arm 1	0	3	0

1 to 10 of 543Source ClinicalTrials.gov

See all 543 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Arm 1	2	3
Total, all-cause mortality	Arm 2	2	6
Total, all-cause mortality	Arm 3	2	9
Total, other adverse events	Arm 1	3	3
Total, other adverse events	Arm 2	6	6
Total, other adverse events	Arm 3	9	9
Total, serious adverse events	Arm 1	0	3
Total, serious adverse events	Arm 2	2	6
Total, serious adverse events	Arm 3	4	9

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P30CA046934	University of Colorado Cancer Center Support Grant	DEGREGORI, JAMES V	UNIVERSITY OF COLORADO DENVER	NATIONAL CANCER INSTITUTE	1988 to 2025

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04925193

GET https://conductscience.org/api/trials/v1/NCT04925193/events?page=2

API reference For AI assistants